GlobeNewswire

Immunicum AB (publ) Announces the Appointment of Sven Rohmann as Chief Executive Officer

Share

Press Release

28 August 2020

Immunicum AB (publ) Announces the Appointment of Sven Rohmann as Chief Executive Officer

Immunicum AB (publ: IMMU.ST) announced today that Sven Rohmann, M.D., Ph.D., MBA, has been appointed Chief Executive Officer (CEO) effective immediately. Bringing 30 years of industry experience from biotechnology and pharmaceutical companies as well as life science investment and company sale and acquisition experience, Dr. Rohmann will be leading Immunicum as it continues to develop ilixadencel, the Company’s cell-based, off-the-shelf immune primer, and other programs for the treatment of solid tumors.

“Sven has an impressive track record of creating value and as a deal maker. He brings a wealth of experience in leading successful biotechnology companies and bringing innovative new medicines all the way through development to product launch,” said Michael Oredsson, Chairman of Immunicum’s Board of Directors. “I am confident that Immunicum will benefit from his vast knowledge of the global biopharmaceutical industry, his strong network and his demonstrated transformative management expertise. We also want to express our gratitude to Alex Karlsson-Parra, who has navigated Immunicum through an important period as the interim CEO, and can now return to his core function as Chief Scientific Officer.”

“I am excited by the opportunity to lead Immunicum and I am fully committed to the Company’s success,” stated Dr. Rohmann. “Ilixadencel is a cell-based immuno-oncology therapy with promising data and I look forward to working together with Immunicum’s strong leadership team to realize its potential in solid tumor indications.”

Dr. Rohmann brings more than three decades of experience as a successful executive in the industry, most recently as acting CEO for Oasmia Pharmaceuticals, a Swedish publicly-listed, commercial-stage oncology company. At Oasmia Pharmaceuticals he successfully raised SEK400 million to launch Apealea®, leading to its subsequent out-licensing for up to $678 million. Earlier in his career, Dr. Rohmann was the founding CEO at Ganymed Pharmaceuticals, where he advanced its lead program from discovery towards clinical Phase II, leading to the acquisition by Astellas. He also held the CEO position at BioVision where he successfully transformed its business resulting in its acquisition by Digilab Inc. Dr. Rohman has extensive big pharma experience from his senior managerial positions at Novartis and Merck KGaA. During his 10-year tenure at Merck KGaA, he built an oncology-focused product portfolio that included the launch of Erbitux®, generating over $2 billion in revenues.

Dr. Rohmann received his medical degree from the University of Mainz, Germany; his Ph.D. in medicine from the Erasmus University in Rotterdam, the Netherlands; and an Executive MBA from the Kellogg School of Management in the USA.

Immunicum plans to host a corporate update event in September where Dr. Rohmann will present himself and the corporate strategy in more detail.

For more information, please contact:

Michael Oredsson, Chairman, Immunicum
Telephone: +61 416717971 
E-mail: info@immunicum.com

INVESTOR RELATIONS

Jonas Rodny
Paues Åberg Communications
Telephone: +46 76 190 90 51
E-mail: ir@immunicum.com

Media Relations

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com

About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Millicom CEO Mauricio Ramos to be keynote speaker at GSMA Thrive Latin America30.11.2020 21:00:00 CETPress release

Millicom CEO Mauricio Ramos to be keynote speaker at GSMA Thrive Latin America Luxembourg, November 30, 2020 – Millicom, a leading provider of cable and mobile services operating as TIGO in Latin America, is pleased to announce that CEO Mauricio Ramos will present at GSMA Thrive Latin America as an invited keynote speaker on December 2. As a global leader in the telecommunications sector, Mr. Ramos will discuss the importance of accelerating connectivity to reinvigorate economies in Latin America and its positive effect on communities. GSMA Thrive Latin America brings together Latin America’s policymakers, digital leaders, and innovators to uncover the opportunities of emerging next-generation technologies and inspire thought leadership to solve the challenges of realizing a truly connected world. Mr. Ramos’s keynote presentation at GSMA Thrive Latin America is scheduled for Wednesday, December 2 at 10:00 a.m. ET. Free registration and the keynote can be accessed here [LINK]. -END- For

GOGL – Declaration of options30.11.2020 19:40:09 CETPress release

The Board of Golden Ocean Group Limited (NASDAQ and OSE: GOGL) (“Golden Ocean” or the “Company”) announced an option holder has exercised options to acquire 50,000 shares in the Company in accordance with the terms previously disclosed. The option exercise will be settled in full with treasury shares held by the Company. Following the delivery of the shares, Golden Ocean will hold a total of 945,000 treasury shares. November 30, 2020 Hamilton, Bermuda The Board of Directors Golden Ocean Group Limited This information is subject to the disclosure requirements of section 5-12 of the Norwegian Securities Trading Act.

Saudi Arabian Oil Company and Shell & AMG Recycling B.V. Sign Agreement to Explore the Feasibility of Building a Recycling “Supercenter” in The Kingdom of Saudi Arabia30.11.2020 18:00:00 CETPress release

Amsterdam, 30 November 2020 (Regulated Information) --- The Saudi Arabian Oil Company (Saudi Aramco), Shell & AMG Recycling B.V. signed a memorandum of understanding (MOU) to evaluate the feasibility of creating a venture in support of Saudi Arabia’s (“The Kingdom”) vision to maximize value from its vast natural resources. The Kingdom is becoming a globally important region for the supply and demand of vanadium, and desires to enable the development of a world class vanadium recycling industry. In support of this initiative, Shell & AMG Recycling B.V., along with Shell Catalysts & Technologies, will explore the feasibility of building a catalyst manufacturing and recycling “supercenter” in The Kingdom. This “supercenter” will enable Saudi Aramco to refine its crudes in an environmentally sustainable manner through the manufacturing of fresh residue upgrading catalysts required to convert heavy oil fractions into valuable products and recycling the resulting spent catalysts and gasifica

Orange Belgium expands its Executive Committee with Isabelle Vanden Eede as Chief Brand, Communication & CSR Officer and Bart Staelens as Chief Transformation & Customer Experience Officer30.11.2020 18:00:00 CETPress release

Press release Brussels, November 30, 2020 Orange Belgium expands its Executive Committee with Isabelle Vanden Eede as Chief Brand, Communication & CSR Officer and Bart Staelens as Chief Transformation & Customer Experience Officer Orange Belgium's Board of Directors validated the nomination of Isabelle Vanden Eede as Chief Brand, Communication & CSR Officer and Bart Staelens as Chief Transformation & Customer Experience Officer, both starting December 1, 2020. Isabelle Vanden Eede, 45 years old, has 23 years of branding and communication experience. She started her career at Ogilvy & Mather Advertising, managing the agencies’ telecom clients. She continued to refine her communication skills at VVL BBDO and Famous agencies, before joining Mobistar in 2010 to be responsible for the residential communication. For the past 10 years Isabelle evolved to Brand & Communication Director, responsible for the rebranding from Mobistar to Orange Belgium. Known for her strategic skills and broad exp

PRESS RELEASE: BIGBEN: Half year results 2020/2130.11.2020 18:00:00 CETPress release

Bigben Press release Lesquin, 30 November 2020 18:00 Half year results 2020/21: ·Current Operating Income: 16.9 M€ (+26.4%) i.e. 12.5% of sales ·Net result: 9.7 M€ (+16.7%) Rise of target for FY 2020/21 Current Operating Income rate: > 12% BIGBEN INTERACTIVE (ISIN FR0000074072) today releases its consolidated results for the first half of fiscal year 2020/21 (from April 1 to September 30) as approved by its Board of directors on 30 November 2020. Consolidated in M€ - IFRS09/202009/2019 ChangeSales135.8127.0+6.9%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 57.3 42.3% 33.4 24.6% 54.9 43.2% 27.7 21.8%+4.4% +20.5% Current operating income In % of Sales Non recurrent items16.9 12.5% (2.3)13.4 10.5% (1.5) +26.4% Operating result In % of Sales14.7 10.8%11.9 9.4%+23.2%Financial result Including currency gain (loss)(1.2) (0.7)(1.0) (0.3) Earnings before tax In % of Sales13.5 9.9%10.9 8.6%+23.0%Tax(3.7)(2.6)Net result for the period In % of Sales9.7 7.2%8.3 6.6% +16.7% Of which Minori

PRESS RELEASE: NACON: Strong increase in profitability in 1st half30.11.2020 18:00:00 CETPress release

Nacon Press release Lesquin, 30 November 2020, 18:00 hrs Strong increase in profitability in 1st half: ·Current Operating Profit : 15.7 M€ (+47.3%) i.e. 18.2% of sales ·Net Result: 9.6 M€ (+46.7%) Outlook: New Upward revision of FY 2020/21 sales: 160-170 M€ NACON (ISIN FR0013482791) today releases its audited consolidated results for the first half of fiscal year 2020/21 (from April 1 to September 30) as approved by its Board of directors on 30 November 2020. Consolidated in M€ - IFRS09/2020 09/2019 (3) ChangeSales86.663.7+35.9%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 45.3 52.3% 30.4 35.1% 39.2 61.5% 23.5 37.0%+15.5% +29.2%Current operating income EBITA In % of Sales Non recurrent items (including Bonus Shares)15.7 18.2% (1.8)10.7 16.8% (1.0) +47.3% Operating result In % of Sales13.9 16.1%9.7 15.2%+43.3%Financial result Including currency gain (loss)(0.8)(0.5) Earnings before tax In % of Sales13.1 15.2%9.3 14.5%+41.8%Tax(3.6)(2.7)Net result for the period In % of Sales9.